Nothing Special   »   [go: up one dir, main page]

MX2018013729A - Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma. - Google Patents

Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma.

Info

Publication number
MX2018013729A
MX2018013729A MX2018013729A MX2018013729A MX2018013729A MX 2018013729 A MX2018013729 A MX 2018013729A MX 2018013729 A MX2018013729 A MX 2018013729A MX 2018013729 A MX2018013729 A MX 2018013729A MX 2018013729 A MX2018013729 A MX 2018013729A
Authority
MX
Mexico
Prior art keywords
crystal form
preparation
new
dapagliflozin
dapagliflozin crystal
Prior art date
Application number
MX2018013729A
Other languages
English (en)
Inventor
Li Xiang
Yu Jun
He Lei;
Wang Jinjia
Du Zuyin
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of MX2018013729A publication Critical patent/MX2018013729A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una forma cristalina nueva de dapagliflozina y un método de preparación y uso de la misma. En particular, se describe una forma cristalina E de 2-cloro-5- (ß-D-glucopiranosa-1-il)- 4'-etoxildifenilmetano y un método de preparación de la misma y una composición farmacéutica que contiene una cantidad terapéuticamente eficaz de la forma cristalina y al uso de la misma en el tratamiento de la diabetes tipo II.
MX2018013729A 2016-05-24 2017-05-22 Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma. MX2018013729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610347924 2016-05-24
PCT/CN2017/085295 WO2017202264A1 (zh) 2016-05-24 2017-05-22 达格列净新晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
MX2018013729A true MX2018013729A (es) 2019-05-02

Family

ID=60412111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013729A MX2018013729A (es) 2016-05-24 2017-05-22 Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma.

Country Status (10)

Country Link
US (1) US10464915B2 (es)
EP (1) EP3466939B1 (es)
JP (1) JP7007300B2 (es)
KR (1) KR20190010578A (es)
CN (1) CN108699020B (es)
BR (1) BR112018071991A2 (es)
ES (1) ES2864153T3 (es)
MX (1) MX2018013729A (es)
TW (1) TWI747906B (es)
WO (1) WO2017202264A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110790735A (zh) * 2018-08-03 2020-02-14 北京海晶生物医药科技有限公司 一种达格列净新晶型n及其制备方法
CN111559997A (zh) * 2019-02-13 2020-08-21 罗欣药业(上海)有限公司 一种达格列净新晶型及其制备方法
CN111689936A (zh) * 2019-03-15 2020-09-22 罗欣药业(上海)有限公司 达格列净新晶型及其制备方法
EP4114365A1 (en) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8283454B2 (en) * 2008-08-22 2012-10-09 Theracos, Inc. Processes for the preparation of SGLT2 inhibitors
BR112014010574A2 (pt) * 2011-10-31 2017-05-02 Scinopharm Taiwan Ltd formas cristalinas e não cristalinas de inibidores sglt2
US8952139B2 (en) * 2011-11-07 2015-02-10 Scinopharm Taiwan, Ltd Process for the preparation of β-C-aryl glucosides
EP2597090A1 (en) 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
CN104829572B (zh) 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法
CN104829573B (zh) 2014-02-11 2018-09-07 江苏豪森药业集团有限公司 达格列净晶型及其制备方法
CN106543124A (zh) * 2015-09-18 2017-03-29 天津市汉康医药生物技术有限公司 达格列净化合物

Also Published As

Publication number Publication date
KR20190010578A (ko) 2019-01-30
WO2017202264A1 (zh) 2017-11-30
ES2864153T3 (es) 2021-10-13
US10464915B2 (en) 2019-11-05
TWI747906B (zh) 2021-12-01
TW201741327A (zh) 2017-12-01
JP2019516706A (ja) 2019-06-20
EP3466939B1 (en) 2021-02-24
CN108699020B (zh) 2021-10-15
CN108699020A (zh) 2018-10-23
JP7007300B2 (ja) 2022-01-24
EP3466939A4 (en) 2019-12-18
EP3466939A1 (en) 2019-04-10
BR112018071991A2 (pt) 2019-02-12
US20190218197A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
SG11201811697SA (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
EP3492096A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES WITH CAS9 PROTEINS AND GUIDE RNA
MY192532A (en) Liquid pharmaceutical composition
EP3858353A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NITM AND ASSOCIATED PHARMACEUTICAL USE
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2018013729A (es) Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma.
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
IL276244A (en) A pharmaceutical preparation for the eyes, a method for its preparation and its application
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2021011189A (es) Composicion farmaceutica inmunorreguladora contra autoinmunidad en diabetes tipo i.
EP3792276A4 (en) NOVEL FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION TO PREVENT OR TREAT CANCER THEREOF
EP3456711A4 (en) CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREFOR
EP4043012A4 (en) MEDICINAL PRODUCTS FOR TREATING ARTERY DISEASES AND USE THEREOF
EP3626727A4 (en) COMPOUND, INTERMEDIATE SYNTHESIS, USE, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD OF NEUROMODULATION
PH12018550008A1 (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
MX2021008941A (es) Moduladores gpr35.
CA3035115C (en) Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
BR112019001130A2 (pt) uso de lactama e composição farmacêutica